Amryt seeks to have rare condition drug approved for payment

The Dublin company is in discussion with regulators in Britain and France to have metreleptin, a treatment for abnormal distribution of fat in the body, approved for payment reimbursement

9th August, 2020
Amryt seeks to have rare condition drug approved for payment
Joe Wiley, Amryt's chief executive, said last week that it is in discussions with the National Institute for Health and Care Excellence

Amryt, the Dublin-based rare drug developer, is in talks with medicines regulators in Britain and other European countries to get its treatments approved for payment reimbursement.

Britain is one of the remaining large European markets where metreleptin, a treatment for lipodystrophy, is yet to be approved for payment following its launch last year. The medical condition involves an abnormal distribution of fat in the body.

Joe Wiley, Amryt's chief executive, said last week that it...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month, €19.99 Monthly thereafter

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Chanelle founder invests €100k in Redesdale Group

Malin shareholders in line for windfall after €119 million cash boost

Icon to restore staff pay as business recovers from virus

Comment: Cutting-edge pharma research can bring investment to Ireland